Floatz logo

DOXORUBICIN

HER2 Positive Breast Carcinoma

Shanghai JMT-Bio Inc.Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
65/ 100

Competitive context

175 Active assets in the HER2 Positive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB
Cyclophosphamide
National University Hospital, Singapore
Phase 3BB
Docetaxel
Ohio State University Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

DOXORUBICIN is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
77 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
76 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →